- Home
- CRF vs COGT Comparison
CRF vs COGT Comparison
Compare CRF & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- COGT
- Stock Information
- Founded
- CRF 1973
- COGT 2014
- Country
- CRF United States
- COGT United States
- Employees
- CRF N/A
- COGT N/A
- Industry
- CRF Finance/Investors Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CRF Finance
- COGT Health Care
- Exchange
- CRF Nasdaq
- COGT Nasdaq
- Market Cap
- CRF 953.9M
- COGT 1.1B
- IPO Year
- CRF N/A
- COGT 2018
- Fundamental
- Price
- CRF $7.78
- COGT $11.89
- Analyst Decision
- CRF
- COGT Strong Buy
- Analyst Count
- CRF 0
- COGT 9
- Target Price
- CRF N/A
- COGT $20.25
- AVG Volume (30 Days)
- CRF 1.1M
- COGT 1.7M
- Earning Date
- CRF 01-01-0001
- COGT 08-05-2025
- Dividend Yield
- CRF 18.10%
- COGT N/A
- EPS Growth
- CRF N/A
- COGT N/A
- EPS
- CRF 1.40
- COGT N/A
- Revenue
- CRF $11,461,786.00
- COGT N/A
- Revenue This Year
- CRF N/A
- COGT N/A
- Revenue Next Year
- CRF N/A
- COGT N/A
- P/E Ratio
- CRF $5.38
- COGT N/A
- Revenue Growth
- CRF 6.53
- COGT N/A
- 52 Week Low
- CRF $5.70
- COGT $3.72
- 52 Week High
- CRF $9.56
- COGT $12.97
- Technical
- Relative Strength Index (RSI)
- CRF 47.26
- COGT 61.75
- Support Level
- CRF $7.66
- COGT $11.41
- Resistance Level
- CRF $7.95
- COGT $12.21
- Average True Range (ATR)
- CRF 0.07
- COGT 0.55
- MACD
- CRF -0.01
- COGT -0.13
- Stochastic Oscillator
- CRF 39.66
- COGT 79.47
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.